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Abstract
Background: To examine the longitudinal utility of a biomarker signature in conjunction with myositis autoantibodies
(autoAbs) as predictors of disease improvement in refractory myositis patients treated with rituximab.
Methods: In the RIM Trial, all subjects received rituximab on 2 consecutive weeks. Using start of treatment as
baseline, serum samples (n = 177) were analyzed at baseline and after rituximab with multiplexed sandwich
immunoassays to quantify type-1 IFN-regulated and other pro-inflammatory chemokines and cytokines. Biomarker
scores were generated for the following pathways: type-1 IFN-inducible (IFNCK), innate, Th1, Th2, Th17 and
regulatory cytokines. Myositis autoAbs (anti-synthetase n = 28, TIF-γ n = 19, Mi-2 n = 25, SRP n = 21, MJ n = 18,
non-MAA n = 24, unidentified autoantibody n = 9, and no autoantibodies n = 33) determined by immunoprecipitation
at baseline, were correlated with outcome measures. Kruskal-Wallis rank sum tests were used for comparisons.
Results: The mean (SD) values for muscle disease and physician global disease activity VAS scores (0–100 mm) were 46
(22) and 49 (19). IFNCK scores (median values) were higher at baseline in subjects with anti-synthetase (43), TIF1-γ (31)
and Mi-2 (30) compared with other autoAb groups (p < 0.001). At 16 weeks after rituximab, anti-synthetase and Mi-2
autoAb positive subjects and non-MAA had a greater improvement in IFNCK scores (− 6.7, − 6.1 and −7.2, p < .001).
Both IFNCK high scores (>30) and autoAb group (Mi-2, non-MAA, and undefined autoantibody) demonstrated the
greatest clinical improvement based on muscle VAS (muscle-interaction p = 0.075).
Conclusion: Biomarker signatures in conjunction with autoAbs help predict response to rituximab in refractory
myositis. Biomarker and clinical responses are greatest at 16 weeks after rituximab.
Background
The idiopathic inflammatory myopathies (IIMs) are a
heterogeneous group of chronic acquired disorders char-
acterized by muscle inflammation and proximal muscle
weakness. These include adult polymyositis (PM), and
both adult and juvenile dermatomyositis (DM) [1]. Both
manual muscle testing (MMT) and serum levels of
muscle enzymes have been used as markers of disease
activity for IIM [2]. However, MMT may sometimes be
inaccurate since muscle strength may be impaired by
disease damage such as chronic scarring, fibrosis or atro-
phy rather than ongoing disease activity; in other cases
weakness cannot be detected in some patients [2]. Simi-
larly, muscle enzyme levels may be inadequate since they
are not specific, may decrease even with ongoing muscle
inflammation and may be elevated in non-inflammatory
myopathies and in denervating conditions [3]. Further-
more, levels of muscle enzymes may be normal in cases
of advanced IIM due to fatty replacement of muscle tis-
sue and in patients with decreased muscle mass [3].
Detection of myositis-specific autoantibodies (MSAs)
can also be helpful in the proper clinical scenario. Exam-
ples of MSAs are autoantibodies directed against ami-
noacyl t-RNA synthetase (anti-syn); the best known is
anti-Jo-1. Anti-Jo-1 is typically found in patients with
antisynthetase syndrome, which is characterized by
myositis, interstitial lung disease (ILD), polyarthritis,
Raynaud’s phenomenon, and mechanic’s hands [3].
Therefore, the detection of anti-Jo-1 has important prog-
nostic value. While very specific for IIM, anti-Jo-1 has a
low sensitivity, and is only present in 20–30 % of PM pa-
tients and even less frequently in DM patients (5–10 %)
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[4]. Since we currently lack adequate indicators for dis-
ease activity, disease prognosis, and response to treat-
ment, newer, more sensitive and responsive biomarkers
are being sought.
Recently, many biomarkers have been identified in IIM
pathogenesis, in particular the pro-inflammatory cyto-
kine IL-6 and type 1 interferon (IFN) regulated genes.
IL-6 modulates the innate and adaptive immune re-
sponses, stimulates tissue inflammation, and has both
B- and T-cell differentiation activity [5]. Type 1 IFNs are
important in up-regulating MHC class I expression,
stimulating activated T cells, activating natural killer
cells, and influencing dendritic cell maturation [5]. The
use of cytokines such as IL-6 and type I IFN signatures
has been studied prospectively by Reed et al. who deter-
mined that type 1 IFN peripheral blood gene “scores,”
chemokine signatures as well as levels of IL-6, IL-8, and
TNF may serve as sensitive and responsive longitudinal
biomarkers of change in disease activity in juvenile and
adult DM [2].
Management goals for IIM include eliminating organ
inflammation and preventing disease complications to re-
duce morbidity and restore quality of life. Corticosteroids
are the standard first-line therapy alone or in combination
with immunosuppressive agents [6]. Unfortunately, many
patients are refractory to corticosteroids and immunosup-
pressive agents, and therefore newer modes of therapy are
currently being studied. B cell depletion (BCD) therapy
with rituximab, which has been used for many years to
treat B-cell lymphomas, has recently gained popularity in
the treatment of autoimmune diseases. The recently pub-
lished Rituximab in Myositis (RIM) trial assessed the ef-
fectiveness of rituximab in refractory adult PM and adult
and juvenile DM, using validated measures of myositis dis-
ease activity and damage, a consensus-driven definition of
improvement, and a unique randomized placebo-phase
trial design [1]. Eighty-three percent of the enrolled sub-
jects met the International Myositis Assessment and Clin-
ical Studies Group preliminary definition of improvement
by the end of the trial. Furthermore, the addition of rituxi-
mab provided a significant steroid-sparing effect between
the start and conclusion of the trial [1].
While biologic therapies such as rituximab have re-
sulted in improved treatment regimens for autoimmune
diseases, the use of biologic therapies in clinical practice
may be limited by concerns over cost. Therefore it is im-
portant to study which patients are most likely to benefit
from biologics, not only to prevent unnecessary costs
but to also prevent adverse effects. Currently there are
no known biomarkers to help predict clinical improve-
ment with rituximab in patients resistant to standard
immunosuppressive therapy. Data presented by Lopez
de Padilla et al., which analyzed this same RIM trial
population, suggested that serum cytokines play an
important role in the pathogenesis of myositis by initiating
and perpetuating various cellular and humoral auto-
immune processes. Using multiplexed sandwich immuno-
assays, they revealed that the interferon chemokine
(IFNCK) and innate cytokine scores before treatment may
help to identify refractory myositis patients responsive to
rituximab [7].
Similarly Aggarwal et al. [8] recently used data from
the RIM trial to identify laboratory predictors of clin-
ical response in myositis patients treated with rituxi-
mab. They analyzed the effect of diverse variables such
as myositis autoantibodies at baseline (anti-synthetase,
−Mi-2, −SRP, −TIF1-γ, −MJ, or other autoantibodies) as
predictors of the time to improvement. They found that
anti-synthetase and anti-Mi-2 autoantibodies strongly
predicted improvement in rituximab-treated refractory
myositis patients [8]. Consequently, taking into account
these recent findings, we examined the longitudinal util-
ity of a biomarker signature in conjunction with myositis
autoantibodies (autoAbs) as biomarkers of disease out-
come in refractory myositis patients treated with B cell
depletion (BCD).
Methods
Subjects and study design
Subjects
This study enrolled 200 subjects with refractory adult
(n = 76) and juvenile DM (n = 48) and adult PM (n =
76). All subjects were part of a previously reported
multicenter clinical trial, ‘Rituximab in Myositis (RIM)
study’ [1].
This study was carried out in accordance with research
protocols approved by Institutional Review Boards of the
Mayo Clinic. Patients and legal guardians signed informed
consent and/or assent, and samples were de-identified in
the laboratory.
Study design
As previously reported [1], the RIM study used a ran-
domized, double-blind, placebo-phase design of intra-
venous rituximab in which refractory subjects were
randomized to either an ‘early-start arm (rituximab at
weeks 0/1, placebo at weeks 8/9) or ‘late-start arm’ (pla-
cebo at weeks 0/1, rituximab at weeks 8/9); therefore all
subjects received rituximab.
Clinical assessment
Clinical assessment and outcome measures were evalu-
ated using a core set of measures (CSMs) described by
the International Myositis Assessment and Clinical Stud-
ies group (IMACS) and used in myositis clinical trials,
including physician global and extramuscular disease
activity scores using a composite score (based on the
investigator’s composite assessment of disease activity on
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the constitutional, cutaneous, skeletal, gastrointestinal,
pulmonary, and cardiac scales of the Myositis Disease
Activity Assessment Tool [MDAAT]. All the measures
including physician and patient global assessments of
disease activity and muscle strength were rated using
100 mm-Visual Analog Scale (VAS) scores (0–100), with
higher scores indicating severe disease activity. All study
participants had their disease activity assessed and blood
samples collected at the time of entry to the study and
at follow up visits.
Autoantibody assessment
MSAs were performed at the rheumatology research
laboratory at the University of Pittsburgh using immu-
noprecipitation techniques as previously described [1].
Patients were grouped based on the presence of MSAs
at baseline into the following groups:anti-synthetase,
−Mi-2, −SRP, −TIF1-γ, −MJ, or other autoantibodies,
as well as no autoantibodies and undefined autoanti-
bodies. Other autoantibodies include those individuals
with myositis-associated autoantibodies not listed pre-
viously; no autoantibodies includes those who had no
autoantibodies detected; and undefined autoantibodies
include those with autoantibodies that are not able to
be defined.
Measurement of serum cytokines and chemokines
As previously described in detail in Reed et al., serum
was isolated from blood drawn and, consequently, multi-
plexed sandwich immunoassays (Meso Scale Discovery,
Rockville, MD) were used to quantitate the serum levels
of IFN regulated chemokines, IFN-α, IFN-γ, and the
serum levels of inflammatory cytokines [9, 8]. A composite
IFN-regulated score was generated based on serum levels
of 3 IFN-regulated chemokines (IP-10, I-TAC and MCP-1),
Th1-(IFN-γ, TNFα, IL2), Th2-(IL-4, IL-5, IL-10, IL-12p70,
IL-13), TH17-(IL-6, IL-17, IL-1β), innate cell-related cyto-
kines (IFN-α, MCP-2, MIG, MIP-1β, IL-8), and regulatory-
cytokines (IL-10 and TNF-α), and normalized cytokine
scores were computed for each group. Our chosen cyto-
kine scoring systems included individually validated
markers by a number of reports in the literature [10–13].
Herein, we included IP-10 within the composite IFN-
regulated chemokine score as a marker of the effects of
IFN and not to suggest it was specifically upregulated only
due to IFN, since many cytokines and chemokines includ-
ing IP-10 are a matrix of overlapping responses.
Statistical methods
Medians, minimums and maximums were used to sum-
marize the chemokine score values. Chemokine scores
were compared between autoantibody groups using
Kruskal-Wallis rank-sum tests. Linear regression models
were used to examine the association between changes
in muscle disease activity and physician global disease
activity VAS according to autoantibody groups and
chemokine scores. Interactions between autoantibody
groups and chemokine scores were examined. We per-
formed our analysis using the muscle and physician glo-
bal VAS specifically since Reed et al. [2] previously




Cytokine and chemokine analysis and clinical informa-
tion were available for 177 of 200 subjects from the RIM
trial. Detailed data on subjects’ demographics, baseline
disease characteristics, safety and clinical outcomes of
the RIM trial were previously reported [1]. Briefly, sub-
jects had longstanding (mean [SD] = 5.4 [6.5] years) and
highly active disease as evidenced by the physician global
disease activity (mean [SD] = 49 [19] mm), patient global
disease activity (mean [SD] = 65 [21] mm) and muscle
activity VAS scores (mean [SD] = 46 [22] mm). Subjects
had failed a mean of 3.1 immunosuppressive agents in
addition to glucocorticoids. [1] We found that IFNCK
scores (median values) were higher at baseline in sub-
jects with anti-synthetase (43), TIF1-γ (31) and Mi-2
(30) compared with other autoAb groups (p < 0.001)
(Table 1, Fig. 1). Regulatory scores were higher at base-
line in subjects with anti-synthetase (31) and non-MAA
(32) vs. other groups (p = 0.01) (Table 1).
Changes from baseline in cytokine scores by
autoantibodies following treatment with rituximab
We compared the distribution of cytokine/chemokine
scores based on autoantibody groups between the base-
line and follow-up time points using the Kruskal-Wallis
rank sum test to determine if there is additional predict-
ability when these assessments are combined Figure 2.
Baseline was defined as the serum cytokine/chemokine
scores based on autoantibody groups before initiation of
rituximab treatment. No significant improvement in
cytokine/chemokine scores based on autoantibody
groups was detected at 8 weeks after the start of treat-
ment. However, at 16 weeks after BCD, anti-synthetase
and Mi-2 autoAb and “undefined” autoAbs positive sub-
ject subgroups had a greater improvement (decrease) in
IFNCK scores (−6.7, −6.1 and −8.7, p < .001), while
TIF1-γ positive subjects worsened by 7.0. The regulatory
score improved at 16 weeks in anti-synthetase (−5.8),
Mi-2 (−3.4) and non-MAA (−7.2) subjects (Table 2).
These three groups stand out when compred to the
other 8 groups (p = 0.028). Th1 scores also improved in
the anti-synthetase, Mi-2, non-MAA and to a lesser ex-
tent in the TIF1-γ group at 16 weeks (p = 0.039) with the
greatest improvement at 24 weeks (p = 0.014), suggesting
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a longer time to improvement if the Th1 score was ele-
vated. The Th17 score remained unchanged.
Changes in muscle VAS at 16 weeks by conjunction of
IFNCK scores and autoAb groups
Regression analyses of clinical improvement were chosen
based on previously published measures that correlated
with IFNCK scores. Muscle VAS changes at 16 weeks re-
vealed a marginally significant interaction between auto-
antibody groups and IFNCK scores at baseline (p = 0.075
for 7°-of-freedom test for interaction). The model
showed that high IFNCK scores at baseline predicted
larger improvements in muscle VAS at 16 weeks after
treatment among subjects in the Mi-2 autoantibody
group (p = 0.019), the no autoantibody group (p = 0.043)
and the undefined autoantibodies group (p = 0.024) com-
pared to the anti-synthetase group. To depict the inter-
action, the changes in muscle VAS at 16 weeks were
compared among autoAbs subgroups by dichotomizing
the subjects based on IFNCK scores into low (<30) and
high (>30) groups (Fig. 3 (a)).
In addition, significant interactions were found for
muscle VAS changes at 16 weeks between AutoAb sub-
groups and the baseline TH-1 (p = 0.008) and TH-17
scores (p = 0.048). Both interactions indicated larger im-
provements in muscle VAS at 16 weeks among subjects
in the non-MAA and undefined autoantibody subgroups
with higher baseline TH-1 and TH-17 scores (Fig. 3 (b
& c)). There were no significant associations or interac-
tions among other autoantibody subgroups for muscle
Table 1 Distribution of cytokines scores at the start of treatment by autoantibodies
Baseline Anti-synthetase TIF SRP MJ MI-2 Other AutoAb No AutoAb Undefined P value
(N = 28) (N = 19) (N = 21) (N = 18) (N = 25) (N = 24) (N = 33) (N = 9)
IFNCKa 43.3 30.9 11.8 18.7 29.9 21.2 13.4 23.2 <.001
(1.4, 100.0) (7.9, 85.9) (1.9, 49.3) (4.1, 66.2) (5.0, 87.2) (2.9, 85.7) (2.5, 72.1) (5.7, 65.4)
TH1 27.9 23.3 19.6 21.9 21.8 26.4 20.7 22.2 0.070
(6.1, 80.5) (13.5, 77.1) (9.5, 88.9) (3.8, 80.6) (17.2, 51.6) (16.6, 49.0) (10.2, 76.2) (12.5, 93.3)
TH2 11.7 10.8 10.1 10.3 9.5 11.7 10.6 10.9 0.12
(5.4, 47.8) (6.8, 52.5) (2.4, 93.7) (2.2, 89.8) (6.5, 21.4) (7.6, 88.4) (6.7, 82.8) (3.5, 34.8)
TH17 28.1 22.8 22.6 27.6 20.7 24.5 22.4 33.1 0.24
(13.0, 79.2) (12.7, 48.9) (13.5, 62.5) (8.6, 74.6) (11.2, 47.8) (15.4, 53.9) (8.9, 40.1) (14.8, 68.5)
Innate 49.3 31.0 28.4 33.3 31.0 33.6 27.0 37.8 0.001
(19.1, 74.8) (15.5, 54.9) (11.7, 54.4) (18.1, 71.2) (17.0, 53.1) (17.4, 61.6) (16.2, 58.5) (18.2, 63.8)
Regulatory 31.1 23.0 21.0 23.1 19.9 32.2 21.1 19.9 0.010
(13.0, 75.6) (10.6, 100.0) (7.5, 100.0) (3.5, 82.1) (15.7, 55.1) (14.6, 75.1) (11.6, 76.8) (15.4, 69.5)
aIFNCK IFN chemokine score
Fig. 1 Distribution of cytokines scores at the start of treatment by autoantibodies. Groupings include the individual autoantibodies listed and
those individuals who had no autoantibodies detected (no autoantibodies), those with myositis-associated autoantibodies but not those listed
(other autoAb) and those with autoantibodies that are not able to be defined (undefined)
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VAS. Results for physician global VAS scores were simi-
lar to those for muscle VAS, but the interactions
between autoantibodies groups and IFNCK, TH-1 and
TH-17 scores did not reach statistical significance (p = 0.09,
p = 0.09 and p = 0.28, respectively).
Discussion
We found that biomarker signatures in conjunction with
autoAbs prior to treatment help guide response to BCD
in refractory myositis. First, we noticed that IFNCK
scores were higher at baseline in patients with certain
autoAb groups such as anti-synthetase, TIF1-γ and
Mi-2. Interestingly, after BCD, patients with (+) anti-
synthetase, Mi-2 autoAb (+) patients and “undefined”
autoAbs had a greater improvement in IFNCK scores
while TIF1-γ (+) patients worsened. Finally we observed
that patients with IFNCK high scores in conjunction with
the autoAb groups anti-synthetase, Mi-2, non-MAA, and
“undefined” autoantibody demonstrated the greatest
clinical improvement in terms of muscle VAS. Therefore,
results of our current study indicate that autoAbs, espe-
cially anti-synthetase, anti-Mi-2, non-MAA, and “un-
defined” autoAbs in conjunction to IFNCK high scores,
are strong predictors of response in rituximab treated
myositis patients in the RIM trial. Since commonly asso-
ciated with immune complexes, a high IFN signature in
Fig. 2 Distribution of cytokines scores of the change from start of treatment to 16 weeks after the start of treatment by autoantibodies





Anti-synthetase TIF SRP MJ MI-2 Other AutoAb No AutoAb Undefined P value
(N = 23) (N = 15) (N = 18) (N = 15) (N = 13) (N = 18) (N = 29) (N = 9)
IFNCKa −6.7 7.0 −0.3 1.2 −6.1 −0.7 2.0 −8.7 <.001
(−80.8, 15.5) (−6.7, 35.3) (−21.9, 28.8) (−41.2, 23.6) (−82.0, 31.6) (−37.7, 18.4) (−30.6, 15.9) (−25.8, 10.5)
TH1 −3.4 −0.9 0.4 0.8 −2.6 −3.6 −0.3 −2.4 0.039
(−44.9, 34.5) (−4.9, 34.9) (−44.0, 63.3) (−20.7, 32.2) (−27.8, 3.6) (−20.7, 17.7) (−59.8, 41.8) (−6.0, 60.3)
TH2 −1.4 0.6 1.1 2.4 0.2 −0.3 1.4 1.3 0.11
(−9.5, 6.1) (−17.5, 5.8) (−7.5, 41.1) (−7.0, 41.4) (−5.7, 8.8) (−51.9, 19.5) (−69.3, 25.5) (−5.1, 23.8)
TH17 −0.0 3.3 3.9 0.0 2.1 0.6 3.0 −1.0 0.50
(−22.4, 26.8) (−20.2, 26.7) (−15.8, 45.7) (−25.3, 43.2) (−18.8, 39.1) (−22.0, 24.5) (−20.4, 43.0) (−13.3, 13.8)
Innate 2.0 3.7 2.7 3.6 −1.0 1.4 7.6 2.1 0.029
(−21.7, 14.9) (−7.8, 24.0) (−6.6, 34.5) (−20.3, 21.6) (−24.3, 8.3) (−14.5, 23.2) (−16.5, 22.1) (−20.1, 14.0)
Regulatory −5.8 −1.9 −0.7 −0.2 −3.4 −7.2 −1.4 −2.9 0.028
(−50.3, 17.1) (−15.4, 15.1) (−15.4, 55.3) (−16.6, 25.0) (−32.2, 9.1) (−50.0, 24.9) (−47.0, 45.7) (−11.7, 12.7)
aIFNCK IFN chemokine score
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Fig. 3 Changes in muscle VAS at 16 weeks by conjuction of serum IFN chemokine scores and autoAb groups. a Changes in Muscle VAS at
16 weeks with serum IFNCK score. b Changes in Muscle VAS at 16 weeks with TH1 score. c Changes in Muscle VAS at 16 weeks with TH17 scores
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the absence of defined autoantibodies will more likely
suggest antibodies not tested for. Our study is novel
since it is the first to demonstrate that subset of
autoAbs have a high correlation with interferon che-
mokine scores.
As previously mentioned, Aggarwal et al. studied the
predictability of autoAbs for clinical improvement in pa-
tients treated with BCD. His results indicated that auto-
Abs, especially anti-synthetase (mainly anti-Jo-1) and
anti-Mi-2, were the strongest predictors of response in
rituximab treated myositis patients in the RIM trial [8].
It is interesting to note that in our study we found that
both anti-synthetase and anti-Mi-2 autoAbs in conjunc-
tion to IFNCK high scores, were among the strongest
predictors of response in rituximab treated myositis pa-
tients in the RIM trial. Therefore, this indicates that
anti-synthetase and anti-Mi-2 have a strong predictive
value for response in rituximab treated myositis patients.
In fact, previous studies have shown anti-Mi-2 to be as-
sociated with a favorable outcome. In a large cohort of
anti-Mi-2 positive patients studied by Hengstman et al.,
the anti-Mi-2 positive patients had a better treatment re-
sponse than the control group of patients with myositis
[8]. Similarly, in a study by Hamaguchi et al., the prog-
nosis of patients with anti–Mi-2 was favorable [14].
Nevertheless, using anti-Mi-2 in conjunction with IFNCK
scores could be more sensitive and specific than using
anti-Mi-2 alone since the two together are a stronger pre-
dictor of response in rituximab treated myositis patients
than anti-Mi-2 by itself.
Anti-synthetase (anti-Jo being the most common and
well known) has been heavily studied as a biomarker of
myositis disease activity. While the IFNCK score did im-
prove in anti-synthetase (+) patients, the change in glo-
bal and muscle disease VAS when put in conjunction
with high IFNCK scores was moderate. This could sug-
gest that there is not much benefit of using anti-
synthetase in conjunction with IFNCK scores. Aggarwal
et al. did find that anti-Jo predicts clinical improvement
[15]. Nevertheless, it is important to note that the
IFNCK score, which helps identify rituximab responsive-
ness in refractory myositis patients, does improve in
anti-synthetase (+) patients.
While Aggarwal et al. found that those with no de-
finable myositis autoantibodies had a worse outcome
[15], suggesting that possessing an autoantibody may
predict a favorable response, we observed that pa-
tients with no autoAbs and “undefined” autoAbs and
higher IFNCK scores were among the autoAbs sub-
groups that demonstrated the greatest clinical improve-
ment. This demonstrates that IFNCK scores could be
useful for discriminating patients who will improve
from those that will not among those with no or un-
defined autoantibodies.
Conclusions
Our study is the first to comprehensively demonstrate
that biomarkers in conjunction with autoAbs are major
predictive factors of response in myositis patients treated
with BCD. This information is useful since biologic ther-
apies such as rituximab have brought improved efficacy
in the realm of autoimmune diseases, but their use in
clinical practice may be limited by concerns over cost.
Predictive models are, therefore, needed to identify those
people with autoimmune diseases with the worst poten-
tial outcomes, who will benefit most from the use of
these drugs. It’s important to bear in mind that predic-
tion methodology should not only be sensitive and spe-
cific, but should be simple enough so that they are not
limited by their complexity or the need for many bio-
markers that will never be routinely measured in the
clinic. Therefore, future studies should focus on design-
ing a mathematically weighted matrix which will serve
as a predictive score for refractory myositis disease using
clinical disease features, interferon gene and chemo-
kines, as well as myositis antibodies in order to predict
which patients will or will not respond to rituximab.
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